ISAL 2025 | Emerging novel approaches for the treatment of young adults with ALL
Wendy Stock, MD, University of Chicago Medical Centre, Chicago, IL, comments on the emerging novel approaches for the treatment of young adults with acute lymphoblastic leukemia (ALL). Dr Stock highlights the potential of targeted agents and CAR T-cells to improve outcomes and reduce treatment duration, while also addressing the challenges of long-term treatment with tyrosine kinase inhibitor therapy, particularly in young women of childbearing age. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are other targeting agents that are going to be used. And then I think one of the other areas that is of interest in terms of the immunotherapies is, is there now or will there be soon an opportunity to test CAR T-cell therapeutics in frontline treatment of patients with ALL in order to both improve outcomes and decrease the length and rigor of the treatments that patients are undergoing. So we have the BH3 mimetics, we have novel immune targeting in T-ALL, and then we have new agents also in B-ALL in terms of immune-targeted agents that will be tested in the future...
There are other targeting agents that are going to be used. And then I think one of the other areas that is of interest in terms of the immunotherapies is, is there now or will there be soon an opportunity to test CAR T-cell therapeutics in frontline treatment of patients with ALL in order to both improve outcomes and decrease the length and rigor of the treatments that patients are undergoing. So we have the BH3 mimetics, we have novel immune targeting in T-ALL, and then we have new agents also in B-ALL in terms of immune-targeted agents that will be tested in the future. I also didn’t mention Ph-positive ALL, which does occur in the young adult population. And one of the big issues now is with the novel TKI antibody approaches, will transplant be needed? How long does one have to continue TKI? These are people who often want to have a family, women who want to have a family, and you can’t be on long-term TKI when you’re pregnant. So these are issues that will have to be addressed in future trials as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
